What $12 Billion in Biotech Exits Taught This CEO About Relationships, Risk, and Near-Death
What does it actually take to build a biotech from nothing... no IP, no programs, no money — into a company acquired by Eli Lilly for over $3 billion?
In this episode of No Spotlight Needed, host Sheetal sits down with Praveen Tipirneni — engineer, physician, and military-trained biotech CEO who built Morphic Therapeutic over nine years, nearly died from an out-of-hospital cardiac arrest midway through, and still came back to close one of biotech's biggest deals of 2024. Now he's doing it again with Caldera Therapeutics.
What we cover:
- Why he sold before Phase 2B data — and the real math behind that call
- Walking into his second board meeting ready to blow up the portfolio and get fired
- Why people invest in people, not science — and the relationships that built every round
- His no-PowerPoint writing culture (yes, before Bezos)
- Why slowing down was always his instinct — and why it worked
- The Friday the stock dropped 30% and the cardiac arrest that followed
- His honest skepticism about AI in drug discovery
- What drew him back to build Caldera
Let’s connect:
LinkedIn: https://www.linkedin.com/in/sheetal-mehta-prasad/
Our Website: https://www.nospotlightneeded.com/
Connect with Praveen: https://www.linkedin.com/in/praveen-tipirneni-42a1a5/
Subscribe to the Channel: https://www.youtube.com/@NoSpotlightNeeded/subscribe
Timestamps:
0:00 - Teaser: almost dying, relationships, and the stock drop Friday
0:40 - Intro: Praveen Tipirneni and the $3B Lilly acquisition
2:13 - Why sell Morphic before Phase 2B data?
3:06 - IBD isn't a disease a small company can commercialize
3:58 - The Olympics ad break analogy
5:41 - Not wanting to be CEO at 45
6:46 - The mentor who said "this is your window"8:26 - First six months at Morphic: sensing something was wrong
9:24 - "I don't just dislike our portfolio — I hate it"
10:47 - Starting from scratch: no IP, no programs, no money
13:13 - Why raising capital is all about relationships
14:26 - "Any biotech is a leap of faith. People invest in people."
15:02 - The Nils story: said no at Series A, led Series B
15:40 - Rajiv at Fidelity and how that relationship made the IPO
16:19 - The mistake: only calling investors when you're raising
17:13 - Morphic's use of Schrödinger and computational chemistry
19:39 - Why Praveen is an AI skeptic in drug discovery
21:50 - Building Morphic's culture: serious, deliberate, written
23:03 - The no-PowerPoint philosophy — before Bezos
25:28 - Tech vs. biotech: why "move fast" doesn't work here
28:22 - Being a conservative CEO — raising less than he could
29:02 - Letting people own their domains: the CFO story
33:25 - The cardiac arrest: stock drop, investor calls, and then nothing
35:30 - Two more arrests by Tuesday. Doctors said he wouldn't survive.
37:20 - "I should have died that day. Every day is not guaranteed."
38:47 - Why hiring great people meant the company ran without him
40:07 - The "break" that didn't last — and what pulled him back in
41:46 - Why he hired no one he knew for the first 2-3 years
43:21 - Cubist: joining a company at negative enterprise value
45:40 - What failures can you point to?
47:58 - CEO vs. Chairman: why they should always be separate
49:04 - Advice to founders: "It's never about the data"
50:46 - Life at Caldera: team-building, wearing every hat
53:18 - IPO as competitive moat and branding event
54:30 - Is biotech a race? What China has changed
54:48 - Free time: racing up mountains and everyone telling him to act his age
55:36 - Closing reflections